JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth

Dexcom’s caller CEO is eyeing maturation successful the planetary marketplace arsenic a cardinal strategy for 2026, caller disconnected the backmost of the institution reporting beardown afloat twelvemonth 2025 (FY25) revenues.

Speaking astatine the ongoing J.P. Morgan Healthcare Conference, Dexcom’s caller CEO Jake Leach said: “We've built our institution based connected enactment successful the US, and we're present going to instrumentality that and use it to the planetary markets, peculiarly our quality to unfastened up entree and sum for radical with CGM to unlock caller opportunities that don’t beryllium today.”

A GlobalData marketplace exemplary reveals that Dexcom, an American headquartered company, held a continuous glucose show (CGM) marketplace stock of 44.7% successful the US successful 2025, 2nd lone to Abbott successful rod presumption with a 48.5% share. However, successful territories including Europe, the Asia Pacific (APAC) portion and the Middle East & Africa (MEA), Dexcom’s marketplace stock is dwarfed by person Abbott.

According to Leach, Dexcom’s planned 2026 merchandise of randomised controlled proceedings results from a ample non-insulin diligent survey (typically benignant 2 diabetics) volition “set the institution up well” for planetary enlargement of sum for this colonisation and truthful lend to its planetary marketplace maturation implicit time.

According to a GlobalData marketplace model, the CGM marketplace is increasing astatine a CAGR of 9.85% and projected to scope a valuation of $15.69bn successful 2035.

Dexcom heads into 2026 connected the backmost of a beardown foundation. The institution achieved FY25 revenues of astir $4.66bn, corresponding to a 16% uplift implicit FY24. The institution present expects to execute FY26 revenues of $5.25bn astatine the apical end.

Leach commented: “We did this by adding a grounds fig of caller patients to Dexcom.”

Leach officially became Dexcom’s caller CEO from 1 January, superseding predecessor Kevin Sayer.

“We exited 2025 with astir 3.5 cardinal progressive customers, which is an summation of implicit 20% from wherever we exited successful 2024,” Leach continued.

Following the merchandise of its FY25 financials connected 12 January, Dexcom’s shares connected the Nasdaq banal speech roseate by 5.31% to $70.98 per stock astatine marketplace close. Dexcom has a marketplace headdress of $27.68bn. Dexcom’s US Food and Drug Administration (FDA) approvals for G7 15-day CGM and Smart Basal, a CGM-integrated basal insulin dosing optimiser for benignant 2 (T2) diabetics, were important factors successful Dexcom’s FY25 success, Leach said, with the recently approved products expected to “ensure” the company’s maturation into 2026.

Leach besides teased what Dexcom is moving connected for G8, the next-generation mentation of its CGM, portion not disclosing a motorboat timeline.